Department of Clinical Sciences, Division of Oncology, Lund University, 221 85 Lund, Sweden.
Department of Surgery, Helsingborg Hospital, 251 87 Helsingborg, Sweden.
Nutrients. 2024 Mar 23;16(7):931. doi: 10.3390/nu16070931.
Previous research has indicated an association between the presence of the vitamin D receptor (VDR) in breast cancer tissue and a favorable prognosis. This study aimed to further evaluate the prognostic potential of VDR located in the nuclear membrane or nucleus (liganded). The VDR protein levels were analyzed using immunohistochemistry in tumor samples from 878 breast cancer patients from Lund, Sweden, included in the Breast Cancer and Blood Study (BCBlood) from October 2002 to June 2012. The follow-up for breast cancer events and overall survival was recorded until 30 June 2019. Univariable and multivariable survival analyses were conducted, both with complete case data and with missing data imputed using multiple imputation by chained equations (MICE). Tumor-specific positive nuclear membrane VDR staining was associated with favorable tumor characteristics and a longer breast cancer free interval (BCFI; HR: 0.64; 95% CI: 0.44-0.95) and overall survival (OS; HR: 0.52; 95% CI: 0.34-0.78). Further analyses indicated that VDR status also was predictive of overall survival when investigated in relation to ER status. There were significant interactions between VDR and invasive tumor size (P = 0.047), as well as mode of detection (P = 0.049). VDR was associated with a longer BCFI in patients with larger tumors (HR: 0.36; 95% CI: 0.14-0.93) or clinically detected tumors (HR: 0.28; 95% CI: 0.09-0.83), while no association was found for smaller tumors and screening-detected tumors. Further studies are suggested to confirm our results and to evaluate whether VDR should and could be used as a prognostic and targetable marker in breast cancer diagnostics.
先前的研究表明,维生素 D 受体(VDR)在乳腺癌组织中的存在与良好的预后相关。本研究旨在进一步评估位于核膜或核内(配体结合)的 VDR 的预后潜力。使用免疫组织化学方法分析了来自瑞典隆德的 878 名乳腺癌患者肿瘤样本中的 VDR 蛋白水平,这些患者来自 2002 年 10 月至 2012 年 6 月的乳腺癌和血液研究(BCBlood)。截至 2019 年 6 月 30 日,记录了乳腺癌事件和总生存的随访情况。进行了单变量和多变量生存分析,同时使用完整病例数据和使用链方程多重插补(MICE)进行缺失数据插补。肿瘤特异性阳性核膜 VDR 染色与良好的肿瘤特征和更长的乳腺癌无复发生存期(BCFI;HR:0.64;95%CI:0.44-0.95)和总生存期(OS;HR:0.52;95%CI:0.34-0.78)相关。进一步的分析表明,当与 ER 状态相关时,VDR 状态也可预测总生存期。VDR 与浸润性肿瘤大小(P = 0.047)以及检测方式(P = 0.049)之间存在显著交互作用。VDR 与较大肿瘤(HR:0.36;95%CI:0.14-0.93)或临床检测肿瘤(HR:0.28;95%CI:0.09-0.83)的 BCFI 较长相关,而对于较小肿瘤和筛查检测肿瘤则没有关联。建议进一步研究以确认我们的结果,并评估 VDR 是否以及能否用作乳腺癌诊断中的预后和靶向标志物。